[:en]Aspects of treatment of prostate cancer metastatic or recurrent[:ro]Aspecte ale tratamentului neoplasmului de prostată metastazat sau recurent[:]

[:en]Cornelia Nitipir (a,b), Bogdan Popescu (b), Irina Radu (b), Maria Alexandra Barbu (a, b)

(a): MD, PhD, senior oncologist, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
(b): MD, oncologist, Elias Emergency University Hospital, Department of Oncology, Bucharest, Romania

Corresponding author: Dr Niţipir Cornelia, e-mail: nitipir2003@yahoo.com


Prostate cancer is currently considered the most common form of cancer that affects the male population. Population screening of men between 55 and 69 years by PSA reduce the rate of death from prostate cancer by 21%.

After diagnosis, prostate cancer should be classified to estimate the aggressiveness of the disease, its prognosis and to assess accurately treatment. In men with low-risk disease, monitoring activities represent a therapeutic option. If intermediate risk may be taken into account radical prostatectomy or external radiotherapy plus androgen deprivation therapy (ADT) may be considered. In patients with high-risk treatment the options include external radiotherapy plus hormonal therapy given for at least 2 years or, in cases well selected, can be considered radical prostatectomy accompanied by extended lymphadenectomy.

In patients with metastatic hormone-naive disease, treatment options are androgen deprivation therapy (ADT) or hormone therapy plus Docetaxel, depending on the presence or absence of visceral damage, and the extent of damage in metastatic bone of the patient’s performance status. In patients with metastatic prostate cancer castration-resistant (CRPC) (after administration of Docetaxel) there are several treatment options, including: Abiraterone, Enzalutamide, Cabazitaxel and Radium-223.

Key words: metastasis, CRPC, PSA, androgen deprivation, prostate cancer

(Full text in Romanian)

* * * * * * * *
You need to subscribe in order to have access to full texts! If you already subscribed, please login here.

* * * * * * * *
Trebuie să vă abonaţi pentru a avea acces la întregul conţinut! Dacă sunteţi deja abonat, trebuie să vă autentificaţi aici.